Overview
GRFS market data
Price History
GRFS price chart
Valuation & Profitability
- P/E (TTM)
- 14.19 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.59 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.67 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 200.2% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.43 – $13.70 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $5.9K · P/B 1.25 · P/S 0.79.
Company news
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Globenewswire Inc · Jul 22, 2026, 6:15 PM
Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous ImmunoglobulinBenzinga · Jul 16, 2026, 12:02 PM
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsightGlobenewswire Inc · May 4, 2026, 5:10 PM